Sanofi SA

Sanofi: Information concerning the total number of voting rights and shares - October 2024

20 ноя 2024 08:11:02 Источник Nasdaq GlobeNewswire

Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria

15 ноя 2024 01:00:00 Источник Nasdaq GlobeNewswire

Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma

14 ноя 2024 11:42:43 Источник Nasdaq GlobeNewswire

Press Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis

06 ноя 2024 01:00:00 Источник Nasdaq GlobeNewswire

Press Release: Sanofi Q3: 15.7% sales growth boosted by earlier-than-anticipated vaccine sales; 2024 business EPS guidance raised due to strong business performance

25 окт 2024 01:30:00 Источник Nasdaq GlobeNewswire

Press Release: Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI

24 окт 2024 08:00:00 Источник Nasdaq GlobeNewswire

Press Release: Sanofi and CD&R partner to fuel Opella’s ambitions in consumer healthcare

21 окт 2024 01:30:00 Источник Nasdaq GlobeNewswire

Press Release: Sanofi and Orano join forces to develop next-generation radioligand medicines

17 окт 2024 01:30:00 Источник Nasdaq GlobeNewswire

Press Release: Sanofi and Orano join forces to develop next-generation radioligand medicines

17 окт 2024 01:30:00 Источник Nasdaq GlobeNewswire

Sanofi: Information concerning the total number of voting rights and shares - September 2024

15 окт 2024 16:05:18 Источник Nasdaq GlobeNewswire

Press Release: Sanofi in discussions to sell a controlling stake in Opella

11 окт 2024 02:30:00 Источник Nasdaq GlobeNewswire

Press Release: New Beyfortus data featured at IDWeek reinforce real-world effectiveness against RSV disease and hospitalization in infants

09 окт 2024 01:00:00 Источник Nasdaq GlobeNewswire

Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD

27 сен 2024 09:35:00 Источник Nasdaq GlobeNewswire

Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD

27 сен 2024 07:00:00 Источник Nasdaq GlobeNewswire

Press Release: Availability of the Q3 2024 Aide mémoire

26 сен 2024 01:30:00 Источник Nasdaq GlobeNewswire

Press Release: Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant

20 сен 2024 18:36:29 Источник Nasdaq GlobeNewswire

Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old

20 сен 2024 07:45:00 Источник Nasdaq GlobeNewswire

Press Release: Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 study

20 сен 2024 05:30:00 Источник Nasdaq GlobeNewswire

Sanofi: Information concerning the total number of voting rights and shares - August 2024

16 сен 2024 12:44:49 Источник Nasdaq GlobeNewswire

Press Release: Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers

12 сен 2024 01:00:00 Источник Nasdaq GlobeNewswire